Boston, MA 09/16/2014 (wallstreetpr) – Investment advisor, Goldman Sachs Group Inc (NYSE:GS) analysts have provided key takeaways from the 2014 Transcatheter Cardiovascular Therapeutics or TPT conference. Accordingly, they have retained their Buy rating on the shares of Abbott Pharmaceuticals (NYSE:ABT) and Edwards Lifesciences Corp (NYSE:EW) while they remained Neutral on St. Jude Medical, Inc. (NYSE:STJ) and Sell on Boston Scientific Corporation (NYSE:BSX).
New Technologies
The brokerage said that the focus during the TCT conference was on transcatheter heart valves or THV with a promise towards cost effectiveness and long-term follow-up data presentation. Aside from these data, its analyst David Roman said that the discussions in the corridors centered on moving down the risk curve to cure their patients besides an opinion that an indication might come sooner than currently contemplated in the U.S.
The brokerage said that it would mode global unit upside of 20% till 2018 to be fuelled in the U.S. by 20%, the European Union by 11% and Japan by 32%. The analyst believes that since there would be healthy unit uptick besides continued technology advancement, pricing was not a big part of the conversation.
Market Share
Goldman Sachs Group Inc (NYSE:GS) believes that new players would continue to struggle for market share. For instance, in Europe, there are seven companies on the market but only the top two companies continue to hold over 85% of the market share and there was not much of a change in the last several quarters.
Similarly, in the U.S., the brokerage does not a third commercial challenger till the year 2017 – 2018. Analyst David Roman thinks Edwards would be most levered in view of its pipeline and market position providing key competitive advantages.
Rating of Stocks
Analyst continues to see Edwards Lifesciences Corp (NYSE:EW) as a unique asset since it is poised to deliver multiple periods of big growth in both top line, as well as, the bottom line. He said that his numbers were above the consensus in 2015 estimation. As far as Abbott Pharmaceuticals (NYSE:ABT), he said that there were enough drivers in the pipeline to offer a fledgling device franchise in the external years. However, David Roman believes that a deal could lift its growth structurally. Therefore, he retained his Buy rating on the shares of Edwards Lifesciences and Abbott Laboratories.
For Boston Scientific Corporation (NYSE:BSX), the brokerage sees pressure coming from pipeline disappointments whereas the upside case for St. Jude was looking challenged more. As a result, the analyst maintained Sell rating on Boston Scientific shares and Neutral rating on St. Jude shares.
